Factors associated with event-free survival in Chinese patients with Takayasu's arteritis

被引:3
|
作者
Wei, Yu [1 ]
Zhao, Cheng [1 ]
Liang, Jun [1 ]
Jin, Ziyi [1 ]
Hua, Bingzhu [1 ]
Wang, Hong [1 ]
Zhang, Huayong [1 ]
Feng, Xuebing [1 ]
机构
[1] Nanjing Med Univ, Dept Rheumatol & Immunol, Drum Tower Clin Med Hosp, 321 Zhongshan Rd, Nanjing 210008, Peoples R China
基金
中国国家自然科学基金;
关键词
Cyclophosphamide; Prognosis; Pulmonary hypertension; Takayasu's arteritis; PROGNOSTIC-FACTORS; MANAGEMENT; DIAGNOSIS;
D O I
10.1007/s10067-020-05481-x
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objectives To investigate long-term outcomes of Takayasu's arteritis (TA) and explore the predictive factors associated with poor prognosis. Methods We performed a retrospective study on consecutive TA patients admitted to the Nanjing Drum Tower Hospital during the period from July 2010 to March 2019. Potential factors contributing to adverse outcomes, including death, vascular complications, and vascular stenosis aggravation were assessed by Cox regression analysis. Results Seventy-one individuals were enrolled, in which 90.1% were female. The mean onset age was 29.44 +/- 11.75 years, and mean follow-up time was 3.42 +/- 2.38 years. Adverse outcomes were observed in twenty-five (35.2%) patients, and the 1-, 5-, and 8-year event-free survival was 94.2%, 61.8%, and 29.8% respectively. Univariable Cox regression revealed that pulmonary hypertension (PH) (HR 4.13), high total cholesterol levels (HR 4.49), high LDL cholesterol levels (HR 5.14), and low-dose cyclophosphamide (CTX) treatment (HR 0.53) were associated with adverse outcomes. Among them, only CTX treatment remained significant in multivariable Cox regression analysis (HR 0.62). Interestingly, compared to those ineffective to CTX, the responders had higher immunoglobulin A levels (p < 0.05) but lower CRP levels (p < 0.05). Conclusions Even with vigorous therapy, a large proportion of TA patients may present adverse outcomes along with the development of disease. Low-dose CTX treatment is helpful for a better prognosis.
引用
收藏
页码:1941 / 1948
页数:8
相关论文
共 50 条
  • [21] Fontan fenestration closure and event-free survival
    Imielski, Bartlomiej R.
    Woods, Ronald K.
    Mussatto, Kathleen A.
    Cao, Yumei
    Simpson, Pippa M.
    Tweddell, James S.
    JOURNAL OF THORACIC AND CARDIOVASCULAR SURGERY, 2013, 145 (01): : 183 - 187
  • [22] Symptom Clusters Predict Event-Free Survival in Patients With Heart Failure
    Song, Eun Kyeung
    Moser, Debra K.
    Rayens, Mary K.
    Lennie, Terry A.
    JOURNAL OF CARDIOVASCULAR NURSING, 2010, 25 (04) : 284 - 291
  • [23] Clinical significance and predictive risk factors for event-free survival at 24 months in patients with PTCL, NOS
    Cao, Zheng
    Wang, Xiaojun
    Xue, Xuemin
    Feng, Xiaoli
    ANNALS OF HEMATOLOGY, 2024, 103 (03) : 869 - 883
  • [24] Lycopene Intake Predicts Event-Free Survival in Patients with Heart Failure
    Biddle, Martha J.
    Payne-Emerson, Heather
    Heo, Seongkum
    Song, Eun Kyeung
    Lennie, Terry A.
    Dunbar, Sandi
    Pressler, Susan J.
    Kim, JinShil
    Moser, Debra K.
    CIRCULATION, 2008, 118 (18) : S920 - S920
  • [25] α2C-adrenoceptor polymorphism is associated with improved event-free survival in patients with dilated cardiomyopathy
    Regitz-Zagrosek, V
    Hocher, B
    Bettmann, M
    Brede, M
    Hadamek, K
    Gerstner, C
    Lehmkuhl, HB
    Hetzer, R
    Hein, L
    EUROPEAN HEART JOURNAL, 2006, 27 (04) : 454 - 459
  • [26] Higher dietary lycopene intake is associated with longer cardiac event-free survival in patients with heart failure
    Biddle, Martha
    Moser, Debra
    Song, Eun Kyeung
    Heo, Seongkum
    Payne-Emerson, Heather
    Dunbar, Sandra B.
    Pressler, Susan
    Lennie, Terry
    EUROPEAN JOURNAL OF CARDIOVASCULAR NURSING, 2013, 12 (04) : 377 - 384
  • [27] Event-Free Survival Is a Surrogate for Overall Survival in Patients Treated for Acute Myeloid Leukemia
    Schlenk, Richard F.
    Doehner, Hartmut
    Doehner, Konstanze
    Ganser, Arnold
    Heuser, Michael
    Benner, Axel
    Buyse, Marc E.
    Burzykowski, Tomasz
    BLOOD, 2015, 126 (23)
  • [28] RAS Mutations Are Independently Associated with Decreased Overall Survival and Event-Free Survival in Patients with AML Receiving Induction Chemotherapy
    Ball, Brian J.
    Hsu, Meier
    Devlin, Sean M.
    Famulare, Christopher
    Cai, Sheng F.
    Dunbar, Andrew
    Epstein-Peterson, Zachary D.
    Menghrajani, Kamal
    Glass, Jacob L.
    Taylor, Justin
    Viny, Aaron D.
    Goldberg, Aaron D.
    Tallman, Martin S.
    Stein, Eytan M.
    BLOOD, 2019, 134
  • [29] Thrombomodulin in patients with Takayasu's arteritis
    Lasne, D
    Lefèbvre, C
    Nicaud, V
    Paul, JF
    Aiach, M
    Fiessinger, JN
    THROMBOSIS AND HAEMOSTASIS, 1999, 81 (03) : 469 - 470
  • [30] Assessment of the Frequency of Cardiovascular Risk Factors in Patients with Takayasu's Arteritis
    Alibaz-Oner, Fatma
    Koster, Matthew J.
    Unal, Ali Ugur
    Yildirim, Hale Gulcin
    Cikikci, Ceylan
    Crowson, Cynthia S.
    Makol, Ashima
    Ytterberg, Steven R.
    Matteson, Eric L.
    Direskeneli, Haner
    Warrington, Kenneth J.
    ARTHRITIS & RHEUMATOLOGY, 2016, 68